glp-1/semaglutide-injection-sites">Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, and it works by selectively binding to and activating the GLP-1 receptor — the same receptor the natural hormone uses. That sentence is the FDA label's own, and everything below is read from the prescribing information rather than paraphrased from other summaries of it.
Two things separate semaglutide from the hormone it copies, and both are deliberate chemical modifications. They are what turn a peptide with a half-life of minutes into a once-weekly drug.
What semaglutide is, structurally
Native GLP-1 is destroyed within about two minutes of release, cleaved by the enzyme dipeptidyl peptidase-4. A drug that behaved the same way would be useless. Semaglutide's peptide backbone is produced by yeast fermentation and then altered in two places:
- Position 8 is modified to resist DPP-4. The label states the change is there "to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4". This is what stops the molecule being cleared in minutes.
- Position 26 lysine carries a hydrophilic spacer and a C18 fatty di-acid. The label calls albumin binding "the main protraction mechanism of semaglutide", and this modification is what enables it.
The second one does most of the work. Bound to albumin, semaglutide is shielded from enzymatic breakdown and filtered by the kidney far more slowly. The label puts plasma protein binding at greater than 99%, which it says "results in decreased renal clearance and protection from degradation".
What the receptor activation actually does
The GLP-1 receptor is not confined to the pancreas. Per the label, it "is present in several areas of the brain involved in appetite regulation", and animal studies show semaglutide "distributed to and activated neurons in brain regions involved in regulation of food intake".
The measured downstream effects, from the pharmacodynamics section:
- Reduced calorie intake, an effect the label attributes to appetite: "Semaglutide decreases calorie intake. The effects are likely mediated by affecting appetite."
- Greater fat mass loss than lean mass loss. Stated plainly in the label, and relevant to the common worry about muscle — covered in does GLP-1 cause muscle loss.
- Glucose-dependent insulin and glucagon effects. Semaglutide "stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner".
- Delayed gastric emptying. One line in the label, and the origin of most of the side-effect profile.
Why "glucose-dependent" is the most important phrase in that list
Insulin secretagogues such as sulfonylureas push insulin out regardless of blood glucose, which is why they can cause hypoglycaemia on their own. Semaglutide's effect scales with glucose: when blood sugar is low, the stimulus is not there. That is why the drug carries a low intrinsic hypoglycaemia risk as monotherapy, and why the risk reappears when it is combined with insulin or a sulfonylurea. The mechanism explains the warning, rather than the warning being an arbitrary caution.
Why the side effects follow from the mechanism
Delayed gastric emptying is not a side effect sitting alongside the therapeutic action; it is part of it. Food leaving the stomach more slowly contributes to fullness, and the same slowing produces nausea, early satiety and reflux when it overshoots. This is also why the label warns that semaglutide "may impact absorption of concomitantly administered oral medications" and advises extra monitoring for oral drugs with a narrow therapeutic index. The side-effects timeline follows the titration schedule for the same reason.
Pharmacokinetics, from the label
| Parameter | Value (subcutaneous) |
|---|---|
| Absolute bioavailability | 89% |
| Time to maximum concentration | 1 to 3 days post dose |
| Steady-state concentration at 2.4 mg weekly | ~75 nmol/L |
| Volume of distribution | ~12.5 L |
| Plasma protein binding | >99% (albumin) |
| Apparent clearance | ~0.05 L/h |
| Elimination half-life | ~1 week |
| Time in circulation after the last dose | 5 to 7 weeks |
Injection site does not matter: the label reports similar exposure from the abdomen, thigh or upper arm. Nor do most patient characteristics — it records no clinically significant pharmacokinetic differences by age, sex, race, ethnicity or body weight.
Elimination is metabolic rather than renal. Semaglutide is broken down by "proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain", with the products leaving in urine and faeces. Only about 3% of the dose is excreted in urine as intact semaglutide.
What the one-week half-life means in practice
Three things follow directly from it. Weekly dosing is possible at all. Steady state takes roughly four to five weeks, which is why dose changes are not judged immediately. And the drug is still measurable five to seven weeks after the last injection — the reason the label advises discontinuing at least two months before a planned pregnancy, and the reason stopping is not a clean switch. What happens next is covered in weight regain after stopping.
Same molecule, two routes: what changes and what does not
Semaglutide is now sold as a weekly injection and as a daily tablet, and the mechanism is identical because the molecule is identical. What differs is entirely pharmacokinetic, and the label gives both sets of numbers.
| Injection, 2.4 mg weekly | Tablet, 25 mg daily | |
|---|---|---|
| Time to maximum concentration | 1 to 3 days | 1 hour |
| Steady-state concentration | ~75 nmol/L | ~77 nmol/L |
| Absolute bioavailability | 89% | Substantially lower — the reason the oral dose is roughly ten times larger |
The two steady-state figures being almost the same is the point of the tablet: a much larger oral dose, poorly absorbed, arrives at a comparable circulating concentration. The label is explicit that oral absorption is variable and that this is why the administration rule exists — empty stomach, plain water, and a wait before eating. Miss the rule and the exposure is not the exposure the dose was chosen for.
What the pill route does not change: the half-life, the albumin binding, the receptor, or any of the downstream effects. Details of each oral product are in the Wegovy pill guide and Ozempic tablets.
What the label does not claim
This is the part most summaries leave out, and it is worth stating precisely.
The cardiovascular mechanism is unknown. The SELECT trial showed semaglutide reduces major adverse cardiovascular events, and the label carries the indication — but on mechanism it says only that "the exact mechanism of semaglutide in CV risk reduction in adults has not been established". Weight loss, blood-pressure change and direct vascular effects have all been proposed; none is settled.
The MASH mechanism is not fully understood either. The label says it "may involve multiple pathways mediated by weight loss and other factors", and notes that the relationship between animal models of MASH and the human disease "has not been fully established".
Anyone writing that semaglutide protects the heart "by reducing inflammation" or "by improving endothelial function" is going beyond what the manufacturer will state in its own labelling.
How tirzepatide differs
Tirzepatide activates two receptors rather than one — GLP-1 and GIP — which is the leading explanation for its larger average effect on weight. The dual-agonist mechanism is set out in how tirzepatide works, and the receptor-level difference between the two incretins in GLP-1 vs GIP. For the class as a whole, see the GLP-1 receptor agonist drug class.
For the same molecule described in plain terms — what it does to appetite, what the trials measured, and what happens when you stop — read how semaglutide works for weight loss.
Scientific References
3 sources- 1
U.S. Food and Drug Administration
WEGOVY (semaglutide) — Prescribing Information, sections 11 Description, 12.1 Mechanism of Action, 12.2 Pharmacodynamics, 12.3 Pharmacokinetics
DailyMed / FDA · 2026
NIH - 2
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT)
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
New England Journal of Medicine · 389(24) · 2023PMID: 37952131
NEJM - 3
Drucker DJ
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Cell Metabolism · 27(4) · 2018PMID: 29617641
PubMed
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is the mechanism of action of semaglutide?
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor. The receptor is present in several brain regions involved in appetite regulation, and activating it reduces calorie intake, stimulates insulin and suppresses glucagon in a glucose-dependent way, and delays gastric emptying. Those four effects are what the FDA label records.
Why does semaglutide last a week when natural GLP-1 lasts minutes?
Two structural modifications. Position 8 is altered to resist degradation by dipeptidyl peptidase-4, the enzyme that clears native GLP-1 within about two minutes. Position 26 lysine carries a hydrophilic spacer and a C18 fatty di-acid, which binds the molecule to plasma albumin — the label calls this the main protraction mechanism. Binding exceeds 99%, which slows renal clearance and shields the peptide from breakdown, giving an elimination half-life of roughly one week.
What does glucose-dependent insulin secretion mean?
It means the insulin effect scales with blood sugar rather than happening regardless of it. Sulfonylureas push insulin out whatever the glucose level, which is why they can cause hypoglycaemia alone. Semaglutide's stimulus falls away when glucose is low, so its intrinsic hypoglycaemia risk as monotherapy is low. The risk returns when it is combined with insulin or a sulfonylurea, which is why that combination is flagged.
How long does semaglutide stay in your system?
About 5 to 7 weeks after the last dose, according to the label, which follows from an elimination half-life of approximately one week. Steady state takes roughly four to five weeks to reach. Elimination is mainly metabolic — proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid sidechain — with only about 3% of the dose excreted in urine as intact semaglutide.
How does semaglutide reduce cardiovascular risk?
The mechanism is not known. The SELECT trial demonstrated a reduction in major adverse cardiovascular events and the indication is on the label, but the label states that the exact mechanism of semaglutide in cardiovascular risk reduction has not been established. Weight loss, blood-pressure reduction and direct vascular effects have all been proposed, and none is settled. Sources that state a definite mechanism are going beyond the labelling.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.